

Peter J Leary

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/342785/publications.pdf>

Version: 2024-02-01

56
papers

1,197
citations

516710

16
h-index

395702

33
g-index

56
all docs

56
docs citations

56
times ranked

1691
citing authors

#	ARTICLE	IF	CITATIONS
1	The Diastolic Pulmonary Gradient Does Not Predict Survival in Patients With Pulmonary Hypertension Due to Left Heart Disease. <i>JACC: Heart Failure</i> , 2015, 3, 9-16.	4.1	151
2	Prognostic value of the pre-transplant diastolic pulmonary artery pressure to pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 289-297.	0.6	123
3	Volume Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1837-1844.	3.2	89
4	Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease. <i>Circulation: Heart Failure</i> , 2018, 11, e004436.	3.9	85
5	Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 868-876.	0.6	76
6	Protocol for Exercise Hemodynamic Assessment: Performing an Invasive Cardiopulmonary Exercise Test in Clinical Practice. <i>Pulmonary Circulation</i> , 2015, 5, 610-618.	1.7	68
7	Traffic-related Air Pollution and the Right Ventricle. The Multi-ethnic Study of Atherosclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1093-1100.	5.6	54
8	Histamine H ₂ Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1544-1552.	2.8	54
9	A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1576-1582.	3.2	47
10	Three-Dimensional Analysis of Right Ventricular Shape and Function in Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2012, 2, 34-40.	1.7	46
11	Impact of the New Pulmonary Hypertension Definition on Heart Transplant Outcomes. <i>Chest</i> , 2020, 157, 151-161.	0.8	31
12	Pulmonary Arterial Compliance Improves Rapidly After Left Ventricular Assist Device Implantation. <i>ASAIO Journal</i> , 2017, 63, 139-143.	1.6	30
13	Pulmonary Arterial Elastance and INTERMACS-Defined Right Heart Failure Following Left Ventricular Assist Device. <i>Circulation: Heart Failure</i> , 2019, 12, e005923.	3.9	28
14	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. <i>European Respiratory Journal</i> , 2021, 57, 2000414.	6.7	24
15	Maternal, Perinatal, and Postneonatal Outcomes in Women With Chronic Heart Disease in Washington State. <i>Obstetrics and Gynecology</i> , 2012, 120, 1283-1290.	2.4	19
16	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 289-299.	0.6	19
17	H ₂ Receptor Antagonists and Right Ventricular Morphology: The MESA Right Ventricle Study. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1379-1386.	3.2	18
18	Accuracy of Doppler blood pressure measurement in continuous-flow left ventricular assist device patients. <i>ESC Heart Failure</i> , 2019, 6, 793-798.	3.1	17

#	ARTICLE	IF	CITATIONS
19	A cardioprotective role for platelet-activating factor through NOS-dependent <i>S</i> -nitrosylation. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2775-H2784.	3.2	16
20	NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1533-1545.	5.6	14
21	Pulmonary Hypertension in the Context of Heart Failure With Preserved Ejection Fraction. Chest, 2021, 160, 2232-2246.	0.8	14
22	Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 T	1.6	13
23	Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension. Chest, 2021, 159, 1586-1597.	0.8	13
24	Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study. Journal of Heart and Lung Transplantation, 2020, 39, 45-52.	0.6	12
25	Associations of Angiopoietins With Heart Failure Incidence and Severity. Journal of Cardiac Failure, 2021, 27, 786-795.	1.7	12
26	Pentraxin-3 and the Right Ventricle: The Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study. Pulmonary Circulation, 2014, 4, 250-259.	1.7	11
27	Pulmonary Hypertension in Congenital Heart Disease. Cardiology Clinics, 2015, 33, 599-609.	2.2	11
28	H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1638-1641.	5.6	11
29	Pericardial Fat and Right Ventricular Morphology: The Multi-Ethnic Study of Atherosclerosis- Right Ventricle Study (MESA-RV). PLoS ONE, 2016, 11, e0157654.	2.5	8
30	Accuracy of Doppler blood pressure measurement in HeartMate 3 ventricular assist device patients. ESC Heart Failure, 2020, 7, 4241-4246.	3.1	7
31	What are the side effects? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 240, 386-391.	1.7	6
32	A novel approach to perioperative risk assessment for patients with pulmonary hypertension. ERJ Open Research, 2021, 7, 00257-2021.	2.6	6
33	Von Willebrand Factor and the Right Ventricle (the MESA-Right Ventricle Study). American Journal of Cardiology, 2012, 110, 1846-1851.	1.6	5
34	Antacid use and subclinical interstitial lung disease: the MESA study. European Respiratory Journal, 2017, 49, 1602566.	6.7	5
35	A Tale of Two Hearts: Patients with Decompensated Right Heart Failure in the Intensive Care Unit. Annals of the American Thoracic Society, 2017, 14, 1025-1030.	3.2	5
36	Terlipressin: Hopes Fulfilled or Dashed?. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 140-142.	4.5	5

#	ARTICLE	IF	CITATIONS
37	A very close call. American Journal of Medicine, 2005, 118, 968-971.	1.5	4
38	Delayed Pneumothorax After Bronchoscopy in a Lung Transplant Patient. Respiratory Care, 2013, 58, e18-e19.	1.6	4
39	Right Atrial Pacing to Improve Acute Hemodynamics in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 508-511.	5.6	4
40	Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study. Journal of Heart and Lung Transplantation, 2022, 41, 619-625.	0.6	4
41	Endothelial-derived von Willebrand factor accelerates fibrin clotting within engineered microvessels. Journal of Thrombosis and Haemostasis, 2022, 20, 1627-1637.	3.8	4
42	Mineral Metabolism and the Right Ventricle: The Multi-Ethnic Study of Atherosclerosis (MESA). American Journal of Kidney Diseases, 2015, 65, 521-523.	1.9	3
43	Causality, Correlation, and Cardiac Disease. Circulation: Cardiovascular Imaging, 2016, 9, e005441.	2.6	3
44	Reply. Journal of the American College of Cardiology, 2016, 68, 2029-2030.	2.8	3
45	Pulmonary Hypertension: Good Intentions, But a Questionable Approach. Annals of the American Thoracic Society, 2018, 15, 664-666.	3.2	3
46	Histamine H ₂ Receptor Antagonists and Heart Failure Risk in Postmenopausal Women: The Women's Health Initiative. Journal of the American Heart Association, 2022, 11, e024270.	3.7	3
47	Risk Prediction and Right Ventricular Dilation in a Single-Institution Pulmonary Arterial Hypertension Cohort. Journal of the American Heart Association, 2022, 11, .	3.7	3
48	Reply. Journal of the American College of Cardiology, 2016, 68, 775-776.	2.8	2
49	Von Willebrand Factor And The Right Ventricle: The MESA-Right Ventricle Study. , 2012, , .		1
50	Elevated Pulmonary Pressure in Survivors of Pediatric Cancer: A Physiologic Finding, Not a Specific Disease. Journal of Clinical Oncology, 2013, 31, 2833-2834.	1.6	1
51	Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1587-1589.	5.6	1
52	Reply: COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?. Annals of the American Thoracic Society, 2021, 18, 1081-1082.	3.2	1
53	Hole in One. American Journal of Medicine, 2009, 122, 626-628.	1.5	0
54	Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. International Journal of Cardiology, 2018, 264, 188.	1.7	0

#	ARTICLE	IF	CITATIONS
55	Which Needle in Which Haystack? Multisystem Care for Pulmonary Hypertension Patients. <i>Annals of the American Thoracic Society</i> , 2019, 16, 979-981.	3.2	0
56	In reply, endothelin-1 and the Anrep effect. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 847.	0.6	0